

Anil Kapoor

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2003017/anil-kapoor-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

331
papers

10,473
citations

38
h-index

97
g-index

393
ext. papers

12,939
ext. citations

3.2
avg. IF

6.37
L-index

#	Paper	IF	Citations
331	Canadian Urological Association guideline: Management of small renal masses - Full-text.. <i>Canadian Urological Association Journal</i> , 2022 , 16, E61-E75	1.2	2
330	Effect of F-DCFPyL PET/CT on the Management of Patients with Recurrent Prostate Cancer: Results of a Prospective Multicenter Registry Trial.. <i>Radiology</i> , 2022 , 211824	20.5	4
329	Canadian Urological Association guideline: Management of small renal masses - Summary of recommendations.. <i>Canadian Urological Association Journal</i> , 2022 , 16, 24-25	1.2	
328	Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. <i>Advances in Radiation Oncology</i> , 2022 , 7, 100899	3.3	0
327	Defining radio-recurrent intra-prostatic target volumes using PSMA-targeted PET/CT and multi-parametric MRI. <i>Clinical and Translational Radiation Oncology</i> , 2022 , 32, 41-47	4.6	1
326	Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis. <i>Journal of Urology</i> , 2022 , 207, 16-24	2.5	4
325	Pathologist workload, work distribution and significant absences or departures at a regional hospital laboratory.. <i>PLoS ONE</i> , 2022 , 17, e0265905	3.7	
324	Impact of stereotactic body radiotherapy (SBRT) in oligoprogressive metastatic disease.. <i>Acta Oncologica</i> , 2022 , 1-9	3.2	
323	Practice-changing publications: Kidney cancer.. <i>Canadian Urological Association Journal</i> , 2022 , 16, E237-E239		
322	Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.. <i>Lancet Oncology</i> , 2022 ,	21.7	6
321	Prediction of Adrenocortical Carcinoma Relapse and Prognosis with a Set of Novel Multigene Panels. <i>Cancers</i> , 2022 , 14, 2805	6.6	0
320	Images - Rare diagnosis of high-grade, undifferentiated pelvic sarcoma for urinary dysfunction in a young man. <i>Canadian Urological Association Journal</i> , 2021 , 15, E192-E194	1.2	
319	Synchronous Metastasis Rates in T1 Renal Cell Carcinoma: A Surveillance, Epidemiology, and End Results Database-based Study. <i>European Urology Focus</i> , 2021 , 7, 818-826	5.1	2
318	Prognostic significance of extent of venous tumor thrombus in patients with non-metastatic renal cell carcinoma: Results from a Canadian multi-institutional collaborative. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 836.e19-836.e27	2.8	2
317	Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: Results from Canadian Kidney Cancer information system. <i>Canadian Urological Association Journal</i> , 2021 , 15, 132-137	1.2	1
316	Development, implementation, and evaluation of a competency-based didactic and simulation-focused boot camp for incoming urology residents: Report of the first three years. <i>Canadian Urological Association Journal</i> , 2021 , 15, 98-105	1.2	2
315	Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists. <i>Canadian Urological Association Journal</i> , 2021 , 15, E90-E96	1.2	2

314	Comparison of a magnetic retrieval device vs. flexible cystoscopy for removal of ureteral stents in renal transplant patients: A randomized controlled trial. <i>Canadian Urological Association Journal</i> , 2021 , 15, E97-E102	1.2	2
313	Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. <i>Canadian Urological Association Journal</i> , 2021 , 15, 84-97	1.2	1
312	Real-Word Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis). <i>Kidney Cancer</i> , 2021 , 5, 21-29	0.6	0
311	Can incomplete metastasectomy impact renal cell carcinoma outcomes? A propensity score matching analysis from a prospective multicenter collaboration. <i>Société Internationale Durologie Journal</i> , 2021 , 2, 82-95	0.1	
310	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021 , 384, 1289-1300	59.2	263
309	Comparison between small renal masses 0-2 cm vs. 2.1-4 cm in size: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 239.e1-239.e7	2.8	0
308	Hypothermia During Partial Nephrectomy for Patients with Renal Tumors: A Randomized Controlled Trial. <i>Journal of Urology</i> , 2021 , 205, 1303-1309	2.5	1
307	PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS4596-TPS4596	2.2	1
306	Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4502-4502	2.2	8
305	Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4554-4554	2.2	0
304	PSMA-PET/CT Registry for Recurrent Prostate Cancer (PREP): Initial findings from a single center.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 5064-5064	2.2	
303	Evolution of anatomic pathology workload from 2011 to 2019 assessed in a regional hospital laboratory via 574,093 pathology reports. <i>PLoS ONE</i> , 2021 , 16, e0253876	3.7	3
302	Lymph node dissection during radical nephrectomy: A Canadian multi-institutional analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 371.e17-371.e25	2.8	1
301	Use of cannabis in urological cancer patients: A review to evaluate risk for cancer development, therapeutic use, and symptom management. <i>Canadian Urological Association Journal</i> , 2021 , 15, 413-419	1.2	0
300	Results from a Canadian consensus forum of key controversial areas in the management of advanced prostate cancer: Recommendations for Canadian healthcare providers. <i>Canadian Urological Association Journal</i> , 2021 , 15, 353-358	1.2	0
299	Patient-reported Quality of Life following Stereotactic Body Radiation Therapy for Primary Kidney Cancer - Results from a Prospective Cohort Study. <i>Clinical Oncology</i> , 2021 , 33, 468-475	2.8	0
298	Achieving the "trifecta" with open versus minimally invasive partial nephrectomy. <i>World Journal of Urology</i> , 2021 , 39, 1569-1575	4	1
297	Prognostic factors in patients with small renal masses: a comparison between . <i>Cancer Causes and Control</i> , 2021 , 32, 119-126	2.8	0

296	Impact of prostate cancer stem cell niches on prostate cancer tumorigenesis and progression. <i>Advances in Stem Cells and Their Niches</i> , 2021 , 5, 177-204	0.2	
295	Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of F-DCFPyL PET/CT Restaging. <i>Advances in Radiation Oncology</i> , 2021 , 6, 100553	3.3	4
294	Impact of Time to Surgery and Surgical Delay on Oncologic Outcomes for Renal Cell Carcinoma. <i>Journal of Urology</i> , 2021 , 205, 78-85	2.5	7
293	Effective Prediction of Prostate Cancer Recurrence through the Network. <i>Cancers</i> , 2021 , 13,	6.6	2
292	Reply By Authors. <i>Journal of Urology</i> , 2021 , 205, 84-85	2.5	
291	Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 1430-1437	8.9	4
290	Tumor Stage and Substage Predict Cancer-specific Mortality After Nephrectomy for Nonmetastatic Renal Cancer: Histological Subtype-specific Validation. <i>European Urology Focus</i> , 2021 ,	5.1	4
289	Differential Expression of a Panel of Ten CNTN1-Associated Genes during Prostate Cancer Progression and the Predictive Properties of the Panel Towards Prostate Cancer Relapse. <i>Genes</i> , 2021 , 12,	4.2	1
288	Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 269-269	2.2	9
287	2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). <i>Canadian Urological Association Journal</i> , 2021 , 15, E81-E90	1.2	4
286	The increasing use of renal tumor biopsy amongst Canadian urologists: When is biopsy most utilized?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 499.e15-499.e22	2.8	0
285	Probiotics for the treatment of depression and anxiety: A systematic review and meta-analysis of randomized controlled trials. <i>Clinical Nutrition ESPEN</i> , 2021 , 45, 75-90	1.3	7
284	Partial nephrectomy in frail patients: Benefits of robot-assisted surgery. <i>Surgical Oncology</i> , 2021 , 38, 101588	2.5	3
283	The impact of sex and age on distribution of metastases in patients with renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2021 , 26, 962-970	4.2	0
282	Partial vs. radical nephrectomy and the risk of all-cause mortality, cardiovascular, and nephrological outcomes. <i>Canadian Urological Association Journal</i> , 2020 , 14, 337-345	1.2	1
281	Contemporary Cytoreductive Nephrectomy Provides Survival Benefit in Clear-cell Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, e730-e738	3.3	4
280	The Oncogenic Potential of the Centromeric Border Protein FAM84B of the 8q24.21 Gene Desert. <i>Genes</i> , 2020 , 11,	4.2	5
279	Contributions of DNA Damage to Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	26

278	Immunohistochemistry Use by Diagnostic Category and Pathologist in 4477 Prostate Core Biopsy Sets Assessed at Two Hospitals. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020 , 28, 259-286	1.9	2
277	Surveillance post-radiofrequency ablation for small renal masses: Recurrence and followup. <i>Canadian Urological Association Journal</i> , 2020 , 14, 398-403	1.2	0
276	Evolving Role of Urologists in the Management of Advanced Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2020 , 47, 271-280	2.9	2
275	Results of the ADAPT Phase 3 Study of Rocabudencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020 , 26, 2327-2336	12.9	21
274	Preoperative frailty predicts adverse short-term postoperative outcomes in patients treated with radical nephroureterectomy. <i>Journal of Surgical Oncology</i> , 2020 , 121, 688-696	2.8	10
273	Management of complex renal cysts in Canada: results of a survey study. <i>BMC Urology</i> , 2020 , 20, 47	2.2	2
272	Outcomes and prognosticators of stage 4 renal cell carcinoma with pathological T4 primary lesion using a large, Canadian, multi-institutional database. <i>Canadian Urological Association Journal</i> , 2020 , 14, 24-30	1.2	2
271	Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2020 , 14, 122-129	1.2	1
270	Controversial issues in the management of patients with advanced prostate cancer: Results from a Canadian consensus forum. <i>Canadian Urological Association Journal</i> , 2020 , 14, E137-E149	1.2	10
269	Cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or targeted therapy (TT): A propensity score-based analysis.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 608-608	2.2	5
268	Small Renal Masses With Tumor Size 0 to 2 cm: A SEER-Based Study and Validation of NCCN Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 1340-1347	7.3	1
267	Canadian Urological Association best practice report: Diagnosis and management of sporadic angiomyolipomas. <i>Canadian Urological Association Journal</i> , 2020 , 14, E527-E536	1.2	2
266	Canadian Urological Association Best Practice Report: Diagnosis and management of sporadic angiomyolipomas. <i>Canadian Urological Association Journal</i> , 2020 , 14, E527-E536	1.2	2
265	Acute care for renal colic in Canadian healthcare - a commentary on emergency department patient flow metrics and treatment options. <i>Canadian Urological Association Journal</i> , 2020 , 14, 265-266	1.2	
264	Genomic and Clinical Correlates of Adrenocortical Carcinoma in an Adult Patient with Li-Fraumeni Syndrome: A Case Report. <i>Current Oncology</i> , 2020 , 28, 226-232	2.8	1
263	Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases. <i>Asian Journal of Andrology</i> , 2020 , 22, 437-438	2.8	1
262	Downregulation of the Raf kinase inhibitory protein (RKIP) in clear cell renal cell carcinoma associates with poor prognosis 2020 , 435-457		1
261	Renal Cell Carcinoma: Comparison between Variant Histology and Clear Cell Carcinoma across All Stages and Treatment Modalities. <i>Journal of Urology</i> , 2020 , 204, 671-676	2.5	12

260	A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, 314-321.e1	3.3	3
259	Does Bone-targeted Therapy Benefit Patients with Metastatic Renal Cell Carcinoma?. <i>Translational Oncology</i> , 2020 , 13, 241-244	4.9	3
258	A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020 , 106, 546-555	4	18
257	Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: The Canadian Kidney Cancer information system experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 799.e1-799.e10	2.8	5
256	Expert and Crowdsourced Evaluation of Image Quality From a Novel Endoscopy Phone Light Adapter. <i>Urology</i> , 2020 , 146, 54-58	1.6	2
255	Construction of a Novel Multigene Panel Potently Predicting Poor Prognosis in Patients with Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	1
254	Determining generalizability of the Canadian Kidney Cancer information system (CKCis) to the entire Canadian kidney cancer population. <i>Canadian Urological Association Journal</i> , 2020 , 14, E499-E506	1.2	4
253	Contactin 1: An Important and Emerging Oncogenic Protein Promoting Cancer Progression and Metastasis. <i>Genes</i> , 2020 , 11,	4.2	5
252	Canadian Update on Surgical Procedures (CUSP) Urology Group consensus for intraoperative hemostasis during minimally invasive partial nephrectomy. <i>Canadian Urological Association Journal</i> , 2020 , 14, E387-E393	1.2	1
251	Does renal tumor biopsies for small renal carcinoma increase the risk of upstaging on final surgery pathology report and the risk of recurrence?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 798.e9-798.e16	2.8	2
250	Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer. <i>Canadian Urological Association Journal</i> , 2020 , 14, 17-23	1.2	11
249	A prospective, randomized, pilot trial of a polyethylene glycol (PEG)-coated collagen patch (Hemopatch) for intraoperative hemostasis during deceased donor renal transplant. <i>Canadian Urological Association Journal</i> , 2020 , 14, E1-E5	1.2	1
248	The role and timing of cytoreductive nephrectomy in the immunotherapy era. <i>European Urology Focus</i> , 2020 , 6, 7-8	5.1	0
247	Application of Hereditary Renal Cell Carcinoma Risk Criteria to a Large Prospective Database. <i>Clinical Oncology</i> , 2020 , 32, e10-e15	2.8	3
246	Histologic Subtype, Tumor Grade, Tumor Size, and Race Can Accurately Predict the Probability of Synchronous Metastases in T2 Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, e610-e618	3.3	3
245	FAM84B promotes prostate tumorigenesis through a network alteration. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919846372	5.4	8
244	Circulating microvesicle protein is associated with renal transplant outcome. <i>Transplant Immunology</i> , 2019 , 55, 101210	1.7	3
243	Morphologic subtyping as a prognostic predictor for survival in papillary renal cell carcinoma: Type 1 vs. type 2. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 721-726	2.8	10

242	High-grade oncocytic tumour (HOT) of kidney in a patient with tuberous sclerosis complex. <i>Histopathology</i> , 2019 , 75, 440-442	7.3	20
241	Impact of Tumor Size on Cancer-Specific Mortality Rate After Local Tumor Ablation in T1a Renal-Cell Carcinoma. <i>Journal of Endourology</i> , 2019 , 33, 606-613	2.7	10
240	Upfront cytoreductive nephrectomy vs. upfront systemic therapy in metastatic kidney cancer. <i>Canadian Urological Association Journal</i> , 2019 , E377-E381	1.2	2
239	The Contributions of Prostate Cancer Stem Cells in Prostate Cancer Initiation and Metastasis. <i>Cancers</i> , 2019 , 11,	6.6	41
238	The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?. <i>Future Oncology</i> , 2019 , 15, 1683-1695	3.6	19
237	Renal cell carcinoma in the Canadian Indigenous population. <i>Current Oncology</i> , 2019 , 26, e367-e371	2.8	1
236	The Central Contributions of Breast Cancer Stem Cells in Developing Resistance to Endocrine Therapy in Estrogen Receptor (ER)-Positive Breast Cancer. <i>Cancers</i> , 2019 , 11,	6.6	34
235	2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). <i>Canadian Urological Association Journal</i> , 2019 , 13, 307-314	1.2	9
234	Diabetes and kidney cancer survival in patients undergoing nephrectomy: A Canadian multi-center, propensity score analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 576.e11-576.e16	2.8	0
233	Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. <i>Canadian Urological Association Journal</i> , 2019 , 13, 343-354	1.2	8
232	Active surveillance in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4516-4516	2.2	5
231	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS4597-TPS4597	2.2	3
230	Efficacy of targeted therapy (TT) after checkpoint inhibitors (CPI) in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 568-568	2.2	2
229	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS684-TPS684	2.2	4
228	Assessment of biochemical recurrence of prostate cancer (Review). <i>International Journal of Oncology</i> , 2019 , 55, 1194-1212	4.4	8
227	A retrospective observational study assessing bone metastases (mets) detection and management of patients (pts) with castration-resistant prostate cancer (CRPC) in Canada.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 161-161	2.2	
226	Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline. <i>Journal of Urology</i> , 2019 , 202, 282-289	2.5	101
225	Renal hypothermia during partial nephrectomy for patients with renal tumours: a randomised controlled clinical trial protocol. <i>BMJ Open</i> , 2019 , 9, e025662	3	3

224	Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of renal mass biopsy in the management of kidney cancer. <i>Canadian Urological Association Journal</i> , 2019 , 13, 377-383	1.2	4
223	Population-Based Analysis Of The Use Of Radium-223 For Bone-Metastatic Castration-Resistant Prostate Cancer In Ontario, And Of Factors Associated With Treatment Completion And Outcome. <i>Cancer Management and Research</i> , 2019 , 11, 9307-9319	3.6	3
222	Balancing efficacy and financial toxicity in the management of metastatic castration-sensitive prostate cancer. <i>Canadian Urological Association Journal</i> , 2019 , 13, 404-405	1.2	
221	The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial. <i>European Journal of Cancer</i> , 2019 , 108, 69-77	7.5	20
220	Comparison of Partial Versus Radical Nephrectomy Effect on Other-cause Mortality, Cancer-specific Mortality, and 30-day Mortality in Patients Older Than 75 Years. <i>European Urology Focus</i> , 2019 , 5, 467-473	5.1	10
219	Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study. <i>European Urology Focus</i> , 2019 , 5, 488-496	5.1	25
218	Canadian Urological Association guideline: Muscle-invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2019 , 230-238	1.2	21
217	Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2019 , 13, 166-174	1.2	7
216	Canadian Urological Association Best Practice Report: Diagnosis and management of radiation-induced hemorrhagic cystitis. <i>Canadian Urological Association Journal</i> , 2019 , 13, 15-23	1.2	7
215	Prostate cancer screening among family physicians in Ontario: An update on attitudes and current practice. <i>Canadian Urological Association Journal</i> , 2018 , 12, E53-E58	1.2	6
214	Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 176-183	3.3	10
213	A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical Recurrence following Radical Local Prostatectomy. <i>Urology</i> , 2018 , 100, 225-231	2.5	6
212	Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy. <i>World Journal of Urology</i> , 2018 , 36, 51-57	4	11
211	The impact of lymph node dissection and positive lymph nodes on cancer-specific mortality in contemporary pT non-metastatic renal cell carcinoma treated with radical nephrectomy. <i>BJU International</i> , 2018 , 121, 383-392	5.6	19
210	Surveillance guidelines based on recurrence patterns for upper tract urothelial carcinoma. <i>Canadian Urological Association Journal</i> , 2018 , 12, 243-251	1.2	5
209	Symptom assessment to guide treatment selection and determine progression in metastatic castration-resistant prostate cancer: Expert opinion and review of the evidence. <i>Canadian Urological Association Journal</i> , 2018 , 12, E415-E420	1.2	2
208	The effect of age on cancer-specific mortality in patients with small renal masses: A population-based analysis. <i>Canadian Urological Association Journal</i> , 2018 , 12, E325-E330	1.2	11
207	Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. <i>Canadian Urological Association Journal</i> , 2018 , 12, 173-180	1.2	11

206	External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>World Journal of Urology</i> , 2018 , 36, 1973-1980	4	5
205	The Effect of Institution Teaching Status on Perioperative Outcomes After Robotic Partial or Radical Nephrectomy. <i>Journal of Endourology</i> , 2018 , 32, 621-629	2.7	7
204	Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2018 , 12, 231-238	1.2	10
203	Anastomosing hemangioma of the kidney: radiologic and pathologic distinctions of a kidney cancer mimic. <i>Current Oncology</i> , 2018 , 25, e220-e223	2.8	11
202	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS710-TPS710	2.2	1
201	Renal cell carcinoma in renal allograft: Case series and review of literature. <i>Urology Annals</i> , 2018 , 10, 229-232	1	6
200	Application of Canadian hereditary renal cell carcinoma risk criteria to a population database.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 621-621	2.2	
199	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS4597-TPS4597	2.2	
198	18F-DCFPyL PET/CT in Oncocytoma. <i>Clinical Nuclear Medicine</i> , 2018 , 43, 921-924	1.7	6
197	Use of targeted therapy in patients with metastatic renal cell carcinoma: clinical and economic impact in a Canadian real-life setting. <i>Current Oncology</i> , 2018 , 25, e576-e584	2.8	14
196	Is there a role for adjuvant therapy after surgery in "high risk for recurrence" kidney cancer? An update on current concepts. <i>Current Oncology</i> , 2018 , 25, e444-e453	2.8	6
195	SDH-deficient renal cell carcinoma - clinical, pathologic and genetic correlates: a case report. <i>BMC Urology</i> , 2018 , 18, 109	2.2	7
194	Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence. <i>Clinical Drug Investigation</i> , 2018 , 38, 1155-1165	3.2	4
193	Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer</i> , 2018 , 124, 3677-3683	6.4	38
192	Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma. <i>Cancer Epidemiology</i> , 2018 , 56, 118-125	2.8	9
191	Thrombotic characteristics of extracellular vesicles derived from prostate cancer cells. <i>Prostate</i> , 2018 , 78, 953-961	4.2	10
190	Effect of African-American race on cancer specific mortality differs according to clear cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma. <i>Cancer Epidemiology</i> , 2018 , 54, 112-118	2.8	8
189	The true malignancy risk of Bosniak III cystic renal lesions: Active surveillance or surgical resection?. <i>Canadian Urological Association Journal</i> , 2018 , 12, E276-E280	1.2	6

188	Biphasic Alteration of Butyrylcholinesterase (BChE) During Prostate Cancer Development. <i>Translational Oncology</i> , 2018 , 11, 1012-1022	4.9	8
187	Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2017 , 35, 355-365	4	27
186	Current management of metastatic renal cell carcinoma: evolving new therapies. <i>Current Opinion in Supportive and Palliative Care</i> , 2017 , 11, 231-237	2.6	11
185	A Multicentered, Propensity Matched Analysis Comparing Laparoscopic and Open Surgery for pT3a Renal Cell Carcinoma. <i>Journal of Endourology</i> , 2017 , 31, 645-650	2.7	7
184	Reply by the Authors. <i>Urology</i> , 2017 , 100, 255	1.6	
183	Autoantibodies against the cell surface-associated chaperone GRP78 stimulate tumor growth via tissue factor. <i>Journal of Biological Chemistry</i> , 2017 , 292, 21180-21192	5.4	11
182	Positive surgical margins during partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer information system (CKCis) collaborative. <i>Canadian Urological Association Journal</i> , 2017 , 11, 182-187	1.2	17
181	Benchmarking quality for renal cancer surgery: Canadian Kidney Cancer information system (CKCis) perspective. <i>Canadian Urological Association Journal</i> , 2017 , 11, 232-237	1.2	5
180	Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path Forward. <i>Kidney Cancer</i> , 2017 , 1, 31-40	0.6	6
179	Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017. <i>Canadian Urological Association Journal</i> , 2017 , 11, 310-320	1.2	6
178	Update from the American Society of Clinical Oncology 2017 Genitourinary Cancers Symposium (ASCO-GU). <i>Canadian Urological Association Journal</i> , 2017 , 11, 159	1.2	78
177	New research in kidney cancer, ASCO 2017. <i>Canadian Urological Association Journal</i> , 2017 , 11, S298-300	1.2	
176	Marital status and gender affect stage, tumor grade, treatment type and cancer specific mortality in T N M renal cell carcinoma. <i>World Journal of Urology</i> , 2017 , 35, 1899-1905	4	19
175	Overexpression of MUC1 and Genomic Alterations in Its Network Associate with Prostate Cancer Progression. <i>Neoplasia</i> , 2017 , 19, 857-867	6.4	22
174	Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era. <i>International Urology and Nephrology</i> , 2017 , 49, 2143-2149	2.3	25
173	Use of SNAPPS Model for Pediatric Outpatient Education. <i>Indian Pediatrics</i> , 2017 , 54, 288-290	1.2	12
172	Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial. <i>JAMA Oncology</i> , 2017 , 3, 913-920	13.4	78
171	Safety, reliability and accuracy of small renal tumour biopsies: results from a multi-institution registry. <i>BJU International</i> , 2017 , 119, 543-549	5.6	45

170	Nuclear transportation of exogenous epidermal growth factor receptor and androgen receptor via extracellular vesicles. <i>European Journal of Cancer</i> , 2017 , 70, 62-74	7.5	32
169	Follow-up imaging after nephrectomy for cancer in Canada: urologists' compliance with guidelines. An observational study. <i>CMAJ Open</i> , 2017 , 5, E834-E841	2.5	0
168	New research in bladder cancer, ASCO 2017. <i>Canadian Urological Association Journal</i> , 2017 , 11, S301-2	1.2	
167	Epidemiology of prostate and kidney cancer in the Aboriginal population of Canada: A systematic review. <i>Canadian Urological Association Journal</i> , 2017 , 11, E222-E232	1.2	3
166	Systematic review of the potential role of cannabinoids as antiproliferative agents for urological cancers. <i>Canadian Urological Association Journal</i> , 2017 , 11, E138-E142	1.2	10
165	First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. <i>Canadian Urological Association Journal</i> , 2017 , 11, 112-117	1.2	25
164	Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4514-4514	2.2	2
163	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS4596-TPS4596	2.2	7
162	Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies. <i>PLoS ONE</i> , 2017 , 12, e0173358	3.7	52
161	Upregulation of FAM84B during prostate cancer progression. <i>Oncotarget</i> , 2017 , 8, 19218-19235	3.3	20
160	Next Generation Quality: Assessing the Physician in Clinical History Completeness and Diagnostic Interpretations Using Funnel Plots and Normalized Deviations Plots in 3,854 Prostate Biopsies. <i>Journal of Pathology Informatics</i> , 2017 , 8, 43	4.4	5
159	Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16078-e16078	2.2	
158	Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16065-e16065	2.2	
157	Checkpoint inhibitors in metastatic renal cell carcinoma patients including elderly subgroups: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4580-4580	2.2	
156	Prostate cancer update from the American Society of Clinical Oncology (ASCO) annual meeting 2016. <i>Canadian Urological Association Journal</i> , 2016 , 10, 137	1.2	78
155	Update from the European Association of Urology (EAU) Annual Meeting 2016. <i>Canadian Urological Association Journal</i> , 2016 , 10, 123	1.2	78
154	Radionuclides. <i>Canadian Urological Association Journal</i> , 2016 , 10, S144-S145	1.2	0
153	Disease progression and kidney function after partial vs. radical nephrectomy for T1 renal cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 486.e17-486.e23	2.8	19

152	The natural history of renal function after surgical management of renal cell carcinoma: Results from the Canadian Kidney Cancer Information System. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 486.e1-486.e7	2.8	25
151	Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia. <i>Therapeutic Advances in Urology</i> , 2016 , 8, 257-271	3.2	11
150	Dataset on the effects of CYB5D2 on the distribution of HeLa cervical cancer cell cycle. <i>Data in Brief</i> , 2016 , 6, 811-6	1.2	4
149	Electrical stimulation with non-implanted electrodes for overactive bladder in adults. <i>Cochrane Database of Systematic Reviews</i> , 2016 , 4, CD010098		14
148	Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer. <i>Cancer Research</i> , 2016 , 76, 1603-14	10.1	35
147	CYB5D2 displays tumor suppression activities towards cervical cancer. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016 , 1862, 556-565	6.9	9
146	Evolving Strategies in the Treatment of Tuberous Sclerosis Complex-associated Angiomyolipomas (TSC-AML). <i>Urology</i> , 2016 , 89, 19-26	1.6	19
145	Amplification of MUC1 in prostate cancer metastasis and CRPC development. <i>Oncotarget</i> , 2016 , 7, 83115-83133	5.3	33
144	Emphysematous pyelonephritis in failed renal allograft: Case report and review of literature. <i>Urology Annals</i> , 2016 , 8, 111-3	1	2
143	Aromatase inhibitors in the treatment of oligozoospermic or azoospermic men: a systematic review of randomized controlled trials. <i>Jornal Brasileiro De Reproducao Assistida</i> , 2016 , 20, 82-8	1.7	14
142	What's new in testosterone deficiency research?. <i>Canadian Urological Association Journal</i> , 2016 , 10, S130-S131	1.2	131
141	Sunitinib: 10 years of clinical experience in the treatment of advanced renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2016 , 10, 235	1.2	78
140	Update on Bladder, Kidney, and Prostate Cancer from the European Society for Medical Oncology (ESMO) Annual Meeting 2016. <i>Canadian Urological Association Journal</i> , 2016 , 10, 223	1.2	78
139	Kidney cancer, ESMO 2016. <i>Canadian Urological Association Journal</i> , 2016 , 10, S227-S230	1.2	3
138	Localized prostate cancer. <i>Canadian Urological Association Journal</i> , 2016 , 10, S138-S139	1.2	2
137	First-line treatment options in metastatic renal cell cancer. <i>Canadian Urological Association Journal</i> , 2016 , 10, S236-S238	1.2	4
136	Intrinsic ureteral endometriosis as a cause of unilateral obstructive uropathy. <i>Canadian Urological Association Journal</i> , 2016 , 10, E119-21	1.2	
135	What's new in renal cancer research?. <i>Canadian Urological Association Journal</i> , 2016 , 10, S132-S133	1.2	

134	What's new in prostate cancer research?. <i>Canadian Urological Association Journal</i> , 2016 , 10, S127-S129	1.2	
133	Chemotherapy research for metastatic prostate cancer. <i>Canadian Urological Association Journal</i> , 2016 , 10, S140-S143	1.2	3
132	Contemporary agents in the management of metastatic castration-resistant prostate cancer. <i>Canadian Urological Association Journal</i> , 2016 , 10, E414-E423	1.2	17
131	Androgen receptor axis-targeted agents. <i>Canadian Urological Association Journal</i> , 2016 , 10, S146-S148	1.2	1
130	Electrical stimulation with non-implanted electrodes for overactive bladder in adults. <i>The Cochrane Library</i> , 2016 , 12, CD010098	5.2	16
129	Impact of resident involvement in endoscopic bladder cancer surgery on pathological outcomes. <i>Scandinavian Journal of Urology</i> , 2016 , 50, 234-8	1.6	11
128	Pathological Upstaging of Clinical T1 to Pathological T3a Renal Cell Carcinoma: A Multi-institutional Analysis of Short-term Outcomes. <i>Urology</i> , 2016 , 94, 154-60	1.6	45
127	The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC). <i>Canadian Urological Association Journal</i> , 2015 , 9, 90-6	1.2	70
126	Renal tumour scoring systems: How useful are they?. <i>Canadian Urological Association Journal</i> , 2015 , 9, 46-7	1.2	3
125	A Prospective Randomized Study of Pfannenstiel Versus Expanded Port Site Incision for Intact Specimen Extraction in Laparoscopic Radical Nephrectomy. <i>Journal of Endourology</i> , 2015 , 29, 913-8	2.7	13
124	Contrast-enhanced Ultrasonography for Surveillance of Radiofrequency-ablated Renal Tumors: A Prospective, Radiologist-blinded Pilot Study. <i>Urology</i> , 2015 , 86, 1174-8	1.6	14
123	The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study. <i>BJU International</i> , 2015 , 116, 72-8	5.6	26
122	Plasma exchange to remove HIT antibodies: dissociation between enzyme-immunoassay and platelet activation test reactivities. <i>Blood</i> , 2015 , 125, 195-8	2.2	63
121	Angiosarcoma of the adrenal gland with concurrent contralateral advanced renal cell carcinoma: A diagnostic and management dilemma. <i>Canadian Urological Association Journal</i> , 2015 , 9, E302-5	1.2	5
120	Renal cell carcinoma and amyopathic dermatomyositis. <i>Canadian Urological Association Journal</i> , 2015 , 9, E340-2	1.2	1
119	Clinical outcomes following laparoscopic management of pT3 renal masses: A large, multi-institutional cohort. <i>Canadian Urological Association Journal</i> , 2015 , 9, 397-402	1.2	5
118	Current Concepts in Genitourinary Oncology: GU-ASCO 2015. <i>Canadian Urological Association Journal</i> , 2015 , 9, 147	1.2	78
117	What's New in Renal Cell Cancer Research? Highlights of GU-ASCO 2015. <i>Canadian Urological Association Journal</i> , 2015 , 9, S154-5	1.2	1

116	What's New in Prostate Cancer Research? Highlights of GU-ASCO 2015. <i>Canadian Urological Association Journal</i> , 2015 , 9, S148-53	1.2	2
115	Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update. <i>Canadian Urological Association Journal</i> , 2015 , 9, 164-70	1.2	15
114	Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2015 , 372, 2387-97	59.2	2371
113	Surgical management of stage T1 renal tumours at Canadian academic centres. <i>Canadian Urological Association Journal</i> , 2015 , 9, 99-106	1.2	7
112	Conditional survival after radical nephroureterectomy for upper tract carcinoma. <i>European Urology</i> , 2015 , 67, 803-12	10.2	54
111	Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4555-4555	2.2	2
110	The proportion and characterization of patients with metastatic renal cell carcinoma who are never treated or have delayed treatment with targeted therapy: Results from a large prospective cohort.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 424-424	2.2	1
109	Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression. <i>Oncotarget</i> , 2015 , 6, 1900-19	3.3	65
108	Canadian guidelines for the management of small renal masses (SRM). <i>Canadian Urological Association Journal</i> , 2015 , 9, 160-3	1.2	36
107	IQGAP2 Displays Tumor Suppression Functions. <i>Journal of Analytical Oncology</i> , 2015 , 4, 86-93		5
106	Differences between the real and the desired worlds in the results of clinical trials. <i>Clinics</i> , 2015 , 70, 618-23		2
105	The impact of renal cell carcinoma histopathological subtype on disease prognosis: A Canadian multi-institutional analysis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 480-480	2.2	
104	Oncology Brief from ASCO 2015: Update on Kidney Cancer and Prostate Cancer. <i>Canadian Urological Association Journal</i> , 2015 , 9, 157	1.2	78
103	Update on cryoablation for treatment of small renal mass: oncologic control, renal function preservation, and rate of complications. <i>Current Urology Reports</i> , 2014 , 15, 396	2.9	12
102	Effect of body mass index on the outcomes of patients with upper and lower urinary tract cancers treated by radical surgery: results from a Canadian multicenter collaboration. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 441-8	2.8	23
101	Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian Upper Tract Collaboration. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 839-45	2.8	35
100	"I told you so": Examining the impact of the surgical safety checklist. <i>Canadian Urological Association Journal</i> , 2014 , 8, E221-2	1.2	1
99	Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus. <i>Canadian Urological Association Journal</i> , 2014 , 8, E398-412	1.2	25

98	The robotic invasion of Canada. <i>Canadian Urological Association Journal</i> , 2014 , 8, E466-7	1.2	2
97	The robotic invasion in Canada. <i>Canadian Urological Association Journal</i> , 2014 , 8, 151	1.2	1
96	The impact of method of distal ureter management during radical nephroureterectomy on tumour recurrence. <i>Canadian Urological Association Journal</i> , 2014 , 8, E845-52	1.2	29
95	¶told you so¶Examining the impact of the surgical safety checklist. <i>Canadian Urological Association Journal</i> , 2014 , 8, 79	1.2	2
94	Canadian content at GU-ASCO 2014: Highlights of research involving Canadian researchers. <i>Canadian Urological Association Journal</i> , 2014 , 8, S16-8	1.2	
93	Update on medical expulsive therapy for distal ureteral stones: Beyond alpha-blockers. <i>Canadian Urological Association Journal</i> , 2014 , 8, 442-5	1.2	12
92	What's new in prostate cancer research? Highlights of GU-ASCO 2014. <i>Canadian Urological Association Journal</i> , 2014 , 8, S8-S12	1.2	2
91	What's new in renal cell cancer research? Highlights of GU-ASCO 2014. <i>Canadian Urological Association Journal</i> , 2014 , 8, S13-5	1.2	
90	PSA screening: And now¶ message from our experts. <i>Canadian Urological Association Journal</i> , 2014 , 8, 387-8	1.2	2
89	New paradigms in the treatment of genitourinary malignancies: GU-ASCO Update 2014. <i>Canadian Urological Association Journal</i> , 2014 , 8, S7	1.2	1
88	Laparoscopic nephrectomy for massive polycystic kidney disease: Updated technique and outcomes. <i>Canadian Urological Association Journal</i> , 2014 , 8, 341-5	1.2	4
87	Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 31.e17-24	2.8	39
86	Laparoscopic management of advanced renal cell carcinoma with renal vein and inferior vena cava thrombus. <i>Urology</i> , 2014 , 83, 812-6	1.6	29
85	Positive surgical margins after partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer Information System database.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 420-420	2.2	1
84	Common reduction of the Raf kinase inhibitory protein in clear cell renal cell carcinoma. <i>Oncotarget</i> , 2014 , 5, 7406-19	3.3	12
83	Contemporary outcomes of pT3 renal cell carcinoma: A Canadian multi-institutional experience.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 434-434	2.2	
82	Clear cell renal cell carcinoma induces fibroblast-mediated production of stromal periostin. <i>European Journal of Cancer</i> , 2013 , 49, 3537-46	7.5	19
81	Comorbidity status does not independently predict survival outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. <i>European Urology</i> , 2013 , 64, 518-9	10.2	1

80	Multifocality rather than tumor location is a prognostic factor in upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 1161-5	2.8	30
79	Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract Collaboration. <i>BJU International</i> , 2013 , 112, 791-7	5.6	38
78	Using the Delphi technique to improve clinical outcomes through the development of quality indicators in renal cell carcinoma. <i>Journal of Oncology Practice</i> , 2013 , 9, e262-7	3.1	31
77	CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update. <i>Canadian Urological Association Journal</i> , 2013 , 7, 231-7	1.2	12
76	Canadian guidelines for postoperative surveillance of upper urinary tract urothelial carcinoma. <i>Canadian Urological Association Journal</i> , 2013 , 7, 306-11	1.2	6
75	Canadian guideline on genetic screening for hereditary renal cell cancers. <i>Canadian Urological Association Journal</i> , 2013 , 7, 319-23	1.2	23
74	Management of advanced kidney cancer: Canadian Kidney Cancer Forum 2013 Consensus Update: Canadian Kidney Cancer Forum 2013. <i>Canadian Urological Association Journal</i> , 2013 , 7, 238-43	1.2	6
73	An alternative approach to deal with the absence of clinical trials: a proportional meta-analysis of case series studies. <i>Acta Cirurgica Brasileira</i> , 2013 , 28, 870-6	1.6	29
72	Cost-utility analysis of radical nephrectomy versus partial nephrectomy in the management of small renal masses: Adjusting for the burden of ensuing chronic kidney disease. <i>Canadian Urological Association Journal</i> , 2013 , 7, 108-13	1.2	16
71	Management of kidney cancer: Canadian Kidney Cancer Forum Consensus Statement. <i>Canadian Urological Association Journal</i> , 2013 , 2, 175	1.2	
70	Regulation of the tumor suppressor PTEN through exosomes: a diagnostic potential for prostate cancer. <i>PLoS ONE</i> , 2013 , 8, e70047	3.7	88
69	Review of the efficacy and safety of cryoablation for the treatment of small renal masses. <i>Canadian Urological Association Journal</i> , 2013 , 7, E38-44	1.2	8
68	Cryoablation vs radiofrequency ablation for the treatment of renal cell carcinoma: a meta-analysis of case series studies. <i>BJU International</i> , 2012 , 110, 510-6	5.6	124
67	Transfer of laparoscopic radical prostatectomy skills from bench model to animal model: a prospective, single-blind, randomized, controlled study. <i>Journal of Urology</i> , 2012 , 187, 1861-6	2.5	29
66	The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience. <i>Urology</i> , 2012 , 79, 840-5	1.6	42
65	Adenovirus-mediated gene transfer of TGF- β to the renal glomeruli leads to proteinuria. <i>American Journal of Pathology</i> , 2012 , 180, 940-951	5.8	19
64	IQGAP2, A candidate tumour suppressor of prostate tumorigenesis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012 , 1822, 875-84	6.9	39
63	Prostate cancer screening: Attitudes and practices of family physicians in Ontario. <i>Canadian Urological Association Journal</i> , 2012 , 6, 188-93	1.2	12

62	Laparoscopic partial nephrectomy: The McMaster University experience. <i>Canadian Urological Association Journal</i> , 2012 , 6, 233-6	1.2	3
61	Management of kidney cancer: canadian kidney cancer forum consensus update 2011. <i>Canadian Urological Association Journal</i> , 2012 , 6, 16-22	1.2	18
60	Regional differences in practice patterns and associated outcomes for upper tract urothelial carcinoma in Canada. <i>Canadian Urological Association Journal</i> , 2012 , 6, 455-62	1.2	5
59	Benign prostatic hyperplasia (BPH) management in the primary care setting. <i>Canadian Journal of Urology</i> , 2012 , 19 Suppl 1, 10-7	0.8	22
58	Comparison of laparoscopic donor nephrectomy with open donor nephrectomy: McMaster University experience and operative technique. <i>Indian Journal of Transplantation</i> , 2011 , 5, 191-194	0.2	0
57	1491 DESIGNING A HIGH-FIDELITY LAPAROSCOPIC PARTIAL NEPHRECTOMY BENCH MODEL: DETERMINING THE TEAR STRENGTH AND RESISTANCE OF A SYNTHETIC SILICONE COMPOSITION. <i>Journal of Urology</i> , 2011 , 185,	2.5	1
56	Characterization of sphere-propagating cells with stem-like properties from DU145 prostate cancer cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2011 , 1813, 683-94	4.9	85
55	A system for laparoscopic surgery ergonomics and skills evaluation. <i>Journal of Endourology</i> , 2011 , 25, 1111-4	2.7	2
54	Current systemic management of metastatic renal cell carcinoma - first line and second line therapy. <i>Current Opinion in Supportive and Palliative Care</i> , 2011 , 5, 211-21	2.6	6
53	Renal histopathology features according to various warm ischemia times in porcine laparoscopic and open surgery model. <i>Canadian Urological Association Journal</i> , 2011 , 5, 40-3	1.2	10
52	Guidelines for the management of the incidentally discovered adrenal mass. <i>Canadian Urological Association Journal</i> , 2011 , 5, 241-7	1.2	75
51	EMannosidase 2C1 attenuates PTEN function in prostate cancer cells. <i>Nature Communications</i> , 2011 , 2, 307	17.4	45
50	Progression-Free Survival as a Primary Endpoint in Clinical Trials of Metastatic Colorectal Cancer. <i>Current Oncology</i> , 2011 , 18, 5-10	2.8	16
49	Commercial renal transplantation: A risky venture? A single Canadian centre experience. <i>Canadian Urological Association Journal</i> , 2011 , 5, 335-40	1.2	6
48	Safety and clinical efficacy of everolimus in the treatment of advanced renal cell carcinoma (RCC). <i>Drug, Healthcare and Patient Safety</i> , 2010 , 2, 85-91	1.6	1
47	Binding of anti-GRP78 autoantibodies to cell surface GRP78 increases tissue factor procoagulant activity via the release of calcium from endoplasmic reticulum stores. <i>Journal of Biological Chemistry</i> , 2010 , 285, 28912-23	5.4	35
46	Spontaneous regression of an untreated lung cancer. <i>Indian Journal of Thoracic and Cardiovascular Surgery</i> , 2010 , 26, 173-175	0.4	
45	Preferred management option for small renal masses: laparoscopic partial nephrectomy. <i>Canadian Urological Association Journal</i> , 2010 , 4, 139-41	1.2	

44	Review of the efficacy and safety of radiofrequency ablation for the treatment of small renal masses. <i>Canadian Urological Association Journal</i> , 2009 , 3, 143-9	1.2	18
43	Task-specific bench model training versus basic laparoscopic skills training for laparoscopic radical prostatectomy: a randomized controlled study. <i>Canadian Urological Association Journal</i> , 2009 , 3, 22-30	1.2	14
42	. <i>Canadian Urological Association Journal</i> , 2009 , 3, 200-204	1.2	10
41	Laparoscopic partial nephrectomy: a challenging operation with a steep learning curve. <i>Canadian Urological Association Journal</i> , 2009 , 3, 119	1.2	4
40	Inhibition of mTOR in kidney cancer. <i>Current Oncology</i> , 2009 , 16 Suppl 1, S33-9	2.8	12
39	Adjuvant and Neoadjuvant Small Molecule Targeted Therapy. <i>Current Oncology</i> , 2009 , 16,	2.8	2
38	Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. <i>Cancer</i> , 2009 , 115, 3618-30	6.4	63
37	Laparoscopic right donor nephrectomy. <i>BJU International</i> , 2009 , 103, 998-1013	5.6	1
36	Obesity and renal cell carcinoma: epidemiology, underlying mechanisms and management considerations. <i>Expert Review of Anticancer Therapy</i> , 2009 , 9, 975-87	3.5	40
35	PTEN inhibits BMI1 function independently of its phosphatase activity. <i>Molecular Cancer</i> , 2009 , 8, 98	42.1	37
34	Specific reduction of fas-associated protein with death domain (FADD) in clear cell renal cell carcinoma. <i>Cancer Investigation</i> , 2009 , 27, 836-43	2.1	3
33	Outcome of third renal allograft retransplants versus primary transplants from paired donors. <i>Transplantation</i> , 2009 , 87, 1214-20	1.8	11
32	Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy. <i>Current Opinion in Supportive and Palliative Care</i> , 2009 , 3, 157-65	2.6	4
31	Computerized Tomography Measurement of Visceral Adiposity Predicts Plasma Adiponectin Levels and Metastatic Disease in Patients with Clear Cell Renal Cell Carcinoma. <i>Current Urology</i> , 2009 , 2, 188-193	1.7	2
30	Laparoscopic pyeloplasty: the updated McMaster University experience. <i>Canadian Urological Association Journal</i> , 2008 , 2, 388-91	1.2	5
29	Treatment of adult rhabdoid renal cell carcinoma with sorafenib. <i>Canadian Urological Association Journal</i> , 2008 , 2, 631-4	1.2	13
28	Lower plasma adiponectin levels are associated with larger tumor size and metastasis in clear-cell carcinoma of the kidney. <i>European Urology</i> , 2008 , 54, 866-73	10.2	59
27	Malignancy in kidney transplant recipients. <i>Drugs</i> , 2008 , 68 Suppl 1, 11-9	12.1	32

26	Bmi1 promotes prostate tumorigenesis via inhibiting p16(INK4A) and p14(ARF) expression. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2008 , 1782, 642-8	6.9	46
25	Laparoscopic nephrectomy with intact specimen extraction for polycystic kidney disease. <i>Journal of Endourology</i> , 2008 , 22, 675-80	2.7	13
24	Systemic therapy for patients with advanced, unresectable ormetastatic renal cell carcinoma: moving to guidelines. <i>Canadian Urological Association Journal</i> , 2007 , 1, S34-40	1.2	1
23	Uncertainty in ultrasound reporting. <i>Canadian Urological Association Journal</i> , 2007 , 1, 255	1.2	
22	Interleukin-2 in the treatment of unresectable or metastatic renal cell cancer: a systematic review and practice guideline. <i>Canadian Urological Association Journal</i> , 2007 , 1, 27-38	1.2	15
21	Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. <i>New England Journal of Medicine</i> , 2007 , 356, 2271-81	59.2	3025
20	Nuclear factor-E2-related factor-1 mediates ascorbic acid induction of osterix expression via interaction with antioxidant-responsive element in bone cells. <i>Journal of Biological Chemistry</i> , 2007 , 282, 22052-61	5.4	63
19	Intact specimen extraction in laparoscopic nephrectomy procedures: Pfannenstiel versus expanded port site incisions. <i>Urology</i> , 2007 , 69, 241-4	1.6	43
18	Co-existence of high levels of the PTEN protein with enhanced Akt activation in renal cell carcinoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2007 , 1772, 1134-42	6.9	25
17	509: The Natural History of Small Renal Masses: A Prospective Multi-Center Canadian Trial. <i>Journal of Urology</i> , 2007 , 177, 169-170	2.5	3
16	ATM activation is accompanied with earlier stages of prostate tumorigenesis. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2006 , 1763, 1090-7	4.9	31
15	Robot-assisted laparoscopic renal artery aneurysm reconstruction. <i>Journal of Vascular Surgery</i> , 2006 , 44, 651-3	3.5	33
14	Laparoscopic management of advanced renal cell carcinoma with level I renal vein thrombus. <i>Urology</i> , 2006 , 68, 514-7	1.6	31
13	A platform of high-efficiency nonviral gene transfer in mouse osteoblast cells in vitro. <i>Molecular Biotechnology</i> , 2006 , 34, 29-35	3	2
12	Comparison of laparoscopic and open nephrectomy for adult polycystic kidney disease: operative challenges and technique. <i>Canadian Journal of Urology</i> , 2006 , 13, 3340-5	0.8	11
11	Terminal loop cutaneous ureterostomy in renal transplantation: an under utilized urinary diversion technique. <i>Journal of Urology</i> , 2005 , 174, 1906-9; discussion 1909	2.5	8
10	Spontaneous fractures in the mouse mutant sfx are caused by deletion of the gulonolactone oxidase gene, causing vitamin C deficiency. <i>Journal of Bone and Mineral Research</i> , 2005 , 20, 1597-610	6.3	37
9	Role of computed tomography with no contrast medium enhancement in predicting the outcome of extracorporeal shock wave lithotripsy for urinary calculi. <i>BJU International</i> , 2005 , 95, 1285-8	5.6	143

8	Identification of a novel Wee1 isoform. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 2005 , 1729, 1-9		3
7	Comparison of laparoscopic radical renal surgery in morbidly obese and non-obese patients. <i>Journal of Endourology</i> , 2004 , 18, 657-60	2.7	32
6	ATM activity contributes to the tumor-suppressing functions of p14ARF. <i>Oncogene</i> , 2004 , 23, 7355-65	9.2	37
5	Laparoscopic versus open partial nephrectomy. <i>Urology</i> , 2004 , 64, 458-61	1.6	60
4	McMaster experience with laparoscopic pyeloplasty. <i>Canadian Journal of Urology</i> , 2004 , 11, 2299-302	0.8	2
3	Apoptotic release of histones from nucleosomes. <i>Journal of Biological Chemistry</i> , 2002 , 277, 12001-8	5.4	90
2	Large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice. <i>Prostate</i> , 1997 , 32, 129-39	4.2	65
1	MUCIN 1 in Prostate Cancer125-138		0